| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Thea Kalebic | |
| P2860 | cites work | Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family | Q24294179 |
| DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters | Q28140428 | ||
| DNA methyltransferase Dnmt1 associates with histone deacetylase activity | Q28141500 | ||
| Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells | Q28142463 | ||
| Histone acetyltransferases: function, structure, and catalysis | Q28204852 | ||
| Retinoblastoma protein represses transcription by recruiting a histone deacetylase | Q28262155 | ||
| Rb interacts with histone deacetylase to repress transcription | Q28263985 | ||
| Methylation matters | Q28364163 | ||
| Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance | Q28378687 | ||
| Cooperation between complexes that regulate chromatin structure and transcription | Q29614769 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| DNA methylation, methyltransferases, and cancer | Q30993657 | ||
| DNA methylation: past, present and future directions | Q31530974 | ||
| Histone acetylation and cancer | Q33632377 | ||
| DNA hypermethylation in tumorigenesis: epigenetics joins genetics | Q33870798 | ||
| DNA methylation and cancer | Q33875819 | ||
| Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. | Q33888431 | ||
| Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients | Q33891633 | ||
| Promoter-region hypermethylation and gene silencing in human cancer | Q33913606 | ||
| Mammalian methyltransferases and methyl-CpG-binding domains: proteins involved in DNA methylation | Q33913612 | ||
| The human histone deacetylase family | Q34119283 | ||
| Participation of histones and histone-modifying enzymes in cell functions through alterations in chromatin structure | Q34199112 | ||
| Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. | Q34254451 | ||
| Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? | Q34290298 | ||
| Towards a pharmacology of DNA methylation | Q34296086 | ||
| Histone acetylation and disease | Q34298969 | ||
| Histone deacetylase inhibitors as new cancer drugs | Q34416846 | ||
| Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours | Q34465751 | ||
| Altered DNA methylation: a secondary mechanism involved in carcinogenesis | Q34504084 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Epigenomics and epigenetic therapy of cancer | Q34583889 | ||
| A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. | Q35976663 | ||
| p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells | Q36489810 | ||
| MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3) | Q36556977 | ||
| Effects of 5-azacytidine and its 2'-deoxyderivative on cell differentiation and DNA methylation | Q38154643 | ||
| Preferential methylation of unmethylated DNA by Mammalian de novo DNA methyltransferase Dnmt3a. | Q40753457 | ||
| A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer | Q40954602 | ||
| Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy | Q41439654 | ||
| Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line | Q41575213 | ||
| Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer | Q42549213 | ||
| Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report | Q43775906 | ||
| The DNA methylation system in proliferating and differentiated cells | Q44314646 | ||
| Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. | Q53440049 | ||
| Apoptosis in colorectal tumour cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. | Q54182323 | ||
| 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers | Q55480673 | ||
| The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas | Q69018368 | ||
| Reduced methyl group acceptance of 1-beta-D-arabinofuranosylcytosine-containing DNA polymers | Q70404442 | ||
| Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers | Q71729088 | ||
| Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise | Q74339007 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | history and philosophy of science | Q5774812 |
| P304 | page(s) | 278-285 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Epigenetic changes: potential therapeutic targets | |
| Epigenetic Changes: Potential Therapeutic Targets | |||
| P478 | volume | 983 |
| Q38161335 | Cumulative Epigenetic Abnormalities in Host Genes with Viral and Microbial Infection during Initiation and Progression of Malignant Lymphoma/Leukemia |
| Q41209870 | EpiDBase: a manually curated database for small molecule modulators of epigenetic landscape |
| Q48944595 | Expression of cell growth negative regulators MEG3 and GADD45γ is lost in most sporadic human pituitary adenomas |
| Q35551099 | Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. |
| Q40399331 | Genetic and epigenetic alterations of RB2/p130 tumor suppressor gene in human sporadic retinoblastoma: implications for pathogenesis and therapeutic approach |
| Q33427040 | Hypermethylation of p15 gene associated with an inferior poor long-term outcome in childhood acute lymphoblastic leukemia |
| Q45088582 | Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells. |
| Q34189725 | Maintenance of a functional higher order chromatin structure: The role of the nuclear matrix in normal and disease states. |
| Q41786430 | Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma |
| Q37962579 | Novel DNA binding domain-based assays for detection of methylated and nonmethylated DNA. |
| Q40258606 | Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. |
| Q53664696 | Tumor-specific exon 1 mutations could be the 'hit event' predisposing Rb2/p130 gene to epigenetic silencing in lung cancer. |
Search more.